Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZONDA benralizumab oral corticosteroid-sparing study in uncontrolled asthma
2013-002523-42Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Percentage reduction in final oral corticosteroid dose compared with baseline while maintaining asthma control. Started Mar 2014; status: completed.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2013-002523-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002523-42.